Cite

HARVARD Citation

    Liu, Z. et al. (2023). CRISPR‐Cas13d effectively targets SARS‐CoV‐2 variants, including Delta and Omicron, and inhibits viral infection. MedComm. 4 (1), p. n/a. [Online]. 
  
Back to record